Literature DB >> 30532285

Magnetic resonance imaging muscle lesions in presumptive canine fibrocartilaginous embolic myelopathy.

Sabrina M Martens1, Stephanie G Nykamp1, Fiona M K James1.   

Abstract

This retrospective cohort study reports the observation of magnetic resonance imaging (MRI) epaxial muscle hyperintensity in dogs diagnosed with presumptive fibrocartilaginous embolic myelopathy (FCEM) (n = 61). It further reports the observation of vertebral column hyperesthesia lasting > 12 hours. The hypothesis tested was that the finding of MRI epaxial muscle hyperintensity correlated with dogs presenting with hyperesthesia. Client-owned dogs diagnosed with presumptive FCEM by specific MRI criteria were included. Statistical analysis was performed using Fisher's exact test. Twenty-three percent (14/61) of MRIs displayed abnormal muscle hyperintensity and 43% (26/61) exhibited vertebral column hyperesthesia. No relationship was found between muscle hyperintensity and pain persisting beyond 12 hours. The muscle hyperintensity remains of unknown significance. That 43% of presumptive FCEM cases have prolonged signs of pain is a higher prevalence than previously reported, and may affect clinical differential diagnoses. This is especially significant in cases in which MRI is not possible and a presumptive diagnosis must be based on the clinical signs.

Entities:  

Mesh:

Year:  2018        PMID: 30532285      PMCID: PMC6237267     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  27 in total

Review 1.  Fibrocartilaginous emboli.

Authors:  T M Neer
Journal:  Vet Clin North Am Small Anim Pract       Date:  1992-07       Impact factor: 2.093

2.  Association of clinical and magnetic resonance imaging findings with outcome in dogs with presumptive acute noncompressive nucleus pulposus extrusion: 42 cases (2000-2007).

Authors:  Luisa De Risio; Vicki Adams; Ruth Dennis; Fraser J McConnell
Journal:  J Am Vet Med Assoc       Date:  2009-02-15       Impact factor: 1.936

3.  Fibrocartilaginous embolism in 75 dogs: clinical findings and factors influencing the recovery rate.

Authors:  G Gandini; S Cizinauskas; J Lang; R Fatzer; A Jaggy
Journal:  J Small Anim Pract       Date:  2003-02       Impact factor: 1.522

4.  Fibrocartilaginous embolic myelopathy in five cats.

Authors:  Jessica S Mikszewski; Thomas J Van Winkle; Mark T Troxel
Journal:  J Am Anim Hosp Assoc       Date:  2006 May-Jun       Impact factor: 1.023

5.  Comparison of clinical signs and outcomes between dogs with presumptive ischemic myelopathy and dogs with acute noncompressive nucleus pulposus extrusion.

Authors:  Joe Fenn; Randi Drees; Holger A Volk; Steven De Decker
Journal:  J Am Vet Med Assoc       Date:  2016-10-01       Impact factor: 1.936

6.  Posterior paralysis due to fibrocartilaginous embolism in two weaner pigs.

Authors:  S V Tessaro; C E Doige; C S Rhodes
Journal:  Can J Comp Med       Date:  1983-04

7.  Usefulness of an early diagnosis for the favorable prognosis of fibrocartilaginous embolism diagnosed by magnetic resonance imaging in 10 small- to middle-sized dogs.

Authors:  Yuya Nakamoto; Tsuyoshi Ozawa; Kengo Katakabe; Koichi Nishiya; Tadahisa Mashita; Yutaka Morita; Nobuhiro Yasuda; Yuki Ishii; Munekazu Nakaichi; Kazuhito Itamoto
Journal:  Vet Res Commun       Date:  2008-05-20       Impact factor: 2.459

Review 8.  Clinical characteristics of canine fibrocartilaginous embolic myelopathy (FCE): a systematic review of 393 cases (1973-2013).

Authors:  K A Bartholomew; K E Stover; N J Olby; S A Moore
Journal:  Vet Rec       Date:  2016-09-28       Impact factor: 2.695

9.  Intravascular cartilaginous emboli in the spinal cord of turkeys.

Authors:  N L Stedman; T P Brown; G N Rowland
Journal:  Avian Dis       Date:  1998 Apr-Jun       Impact factor: 1.577

10.  Fibrocartilaginous embolic myelopathy in a Sumatran tiger (Panthera tigris sumatrae).

Authors:  John M Adaska; Susan Lynch
Journal:  J Zoo Wildl Med       Date:  2004-06       Impact factor: 0.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.